Published in Biochem J on December 01, 1996
Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A (2001) 2.32
Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: mechanism for the antiviral effects of heme oxygenase? Hepatology (2010) 1.75
Dynamics of haem oxygenase-1 expression and bilirubin production in cellular protection against oxidative stress. Biochem J (2000) 1.38
Heme and HO-1 Inhibition of HCV, HBV, and HIV. Front Pharmacol (2012) 1.01
Vinylogous addition of siloxyfurans to benzopyryliums: a concise approach to the tetrahydroxanthone natural products. J Am Chem Soc (2011) 0.91
Biosynthetically Distinct Cytotoxic Polyketides from Setophoma terrestris. European J Org Chem (2015) 0.88
Mesobiliverdin IXα Enhances Rat Pancreatic Islet Yield and Function. Front Pharmacol (2013) 0.78
Gut Bacteria Metabolism Impacts Immune Recovery in HIV-infected Individuals. EBioMedicine (2016) 0.77
Scalable production of biliverdin IXα by Escherichia coli. BMC Biotechnol (2012) 0.77
Changes of the Intestinal Microbiome-Host Homeostasis in HIV-Infected Individuals - A Focus on the Bacterial Gut Microbiome. Eur J Microbiol Immunol (Bp) (2017) 0.75
The Protein Data Bank: a computer-based archival file for macromolecular structures. J Mol Biol (1977) 90.57
Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 12.54
Bilirubin is an antioxidant of possible physiological importance. Science (1987) 11.26
Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A (1988) 10.77
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (1995) 10.13
A geometric approach to macromolecule-ligand interactions. J Mol Biol (1982) 5.71
Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol (1989) 5.15
Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J Virol (1990) 5.01
Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem (1993) 4.80
Rational design of peptide-based HIV proteinase inhibitors. Science (1990) 4.57
Structure-based strategies for drug design and discovery. Science (1992) 3.72
Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science (1994) 3.44
Commercial bilirubin: A trinity of isomers. FEBS Lett (1971) 2.85
Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science (1990) 2.83
Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem (1994) 2.20
Refined three-dimensional structures of two cyanobacterial C-phycocyanins at 2.1 and 2.5 A resolution. A common principle of phycobilin-protein interaction. J Mol Biol (1987) 2.06
Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity. J Virol (1995) 1.78
AIDS in 1988. Sci Am (1988) 1.71
Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions. J Biol Chem (1993) 1.70
Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. J Med Chem (1991) 1.50
Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. Proc Natl Acad Sci U S A (1990) 1.46
Preparation and properties of crystalline biliverdin IX alpha. Simple methods for preparing isomerically homogeneous biliverdin and [14C[biliverdin by using 2,3-dichloro-5,6-dicyanobenzoquinone. Biochem J (1980) 1.29
Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. J Biol Chem (1990) 1.29
Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest (1995) 1.29
Phototherapy for neonatal hyperbilirubinemia: efficacy, mechanism and toxicity. Adv Pediatr (1980) 1.17
Competitive interaction of biliverdin and bilirubin only at the primary bilirubin binding site on human albumin. Anal Biochem (1981) 1.02
Is bilirubin good for you? Clin Perinatol (1990) 1.01
Inhibitors of HIV-1 protease. J Enzyme Inhib (1992) 0.98
Structure of a non-peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design. J Biol Chem (1993) 0.98
Constitutive production of nonenveloped human immunodeficiency virus type 1 particles by a mammalian cell line and effects of a protease inhibitor on particle maturation. Antimicrob Agents Chemother (1994) 0.96
A fast and efficient method for 2D and 3D molecular shape description. J Comput Aided Mol Des (1992) 0.91
Antiviral activity of a bile pigment, biliverdin, against human herpesvirus 6 (HHV-6) in vitro. Microbiol Immunol (1992) 0.89
Rational design of antiviral agents. Annu Rev Pharmacol Toxicol (1989) 0.89
Specific inhibition of HIV-1 protease by boronated porphyrins. J Med Chem (1992) 0.88
Structure determination of the biliverdin apomyoglobin complex: crystal structure analysis of two crystal forms at 1.4 and 1.5 A resolution. J Mol Biol (1995) 0.87
Searching for pharmacophores in large coordinate data bases and its use in drug design. Proc Natl Acad Sci U S A (1989) 0.85
In vitro characterization of nonpeptide irreversible inhibitors of HIV proteases. J Biol Chem (1994) 0.81
In vitro anti-human immunodeficiency virus type 1 activity of biliverdin, a bile pigment. Jpn J Cancer Res (1991) 0.81
Hepatic uptake, transport and metabolism of alkylated bilirubins in Gunn rats and Sprague-Dawley rats. Cell Mol Biol (Noisy-le-grand) (1994) 0.80
Incidence and pattern of jaundice in healthy breast-fed infants during the first month of life. Nurs Res (1993) 0.77
Bilirubin is an antioxidant of possible physiological importance. Science (1987) 11.26
Hydration of proteins and polypeptides. Adv Protein Chem (1974) 6.25
A geometric approach to macromolecule-ligand interactions. J Mol Biol (1982) 5.71
DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des (2001) 4.54
Structural basis of substrate specificity in the serine proteases. Protein Sci (1995) 4.22
Redesigning trypsin: alteration of substrate specificity. Science (1985) 3.70
Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc Natl Acad Sci U S A (2000) 3.06
Cavities in proteins: structure of a metmyoglobin-xenon complex solved to 1.9 A. Biochemistry (1984) 3.05
Replacement of lysine residue 1030 in the putative ATP-binding region of the insulin receptor abolishes insulin- and antibody-stimulated glucose uptake and receptor kinase activity. Proc Natl Acad Sci U S A (1987) 2.99
High throughput protein fold identification by using experimental constraints derived from intramolecular cross-links and mass spectrometry. Proc Natl Acad Sci U S A (2000) 2.96
Hydration of macromolecules. Science (1969) 2.88
The properties of water in biological systems. Annu Rev Biophys Bioeng (1974) 2.62
Splice junctions: association with variation in protein structure. Science (1983) 2.54
The ready isomerization of bilirubin IX- in aqueous solution. Biochem J (1972) 2.50
Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem (2000) 2.50
Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin. Nat Biotechnol (2000) 2.49
Optical diffraction studies of muscle fibers. Biophys J (1973) 2.40
Hydration of macromolecules. IV. Polypeptide conformation in frozen solutions. J Am Chem Soc (1971) 2.34
The enzymatic formation of bilirubin. Ann N Y Acad Sci (1975) 2.34
Molecular cloning and nucleotide sequence of the streptavidin gene. Nucleic Acids Res (1986) 2.30
Thermal expansion of a protein. Biochemistry (1987) 2.25
Structure of two related rat pancreatic trypsin genes. J Biol Chem (1984) 2.24
Using shape complementarity as an initial screen in designing ligands for a receptor binding site of known three-dimensional structure. J Med Chem (1988) 2.20
Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold. J Biol Chem (1997) 2.05
Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci U S A (1999) 2.01
Phytochrome chromophore biosynthesis. Treatment of tetrapyrrole-deficient Avena explants with natural and non-natural bilatrienes leads to formation of spectrally active holoproteins. J Biol Chem (1989) 2.01
Protein folding. J Am Chem Soc (1972) 1.98
The meso-reactivity of porphyrins and related compounds. VI. Oxidative cleavage of the haem system. The four isomeric biliverdins of the IX series. J Chem Soc Perkin 1 (1973) 1.92
The catalytic role of the active site aspartic acid in serine proteases. Science (1987) 1.88
The three-dimensional structure of Asn102 mutant of trypsin: role of Asp102 in serine protease catalysis. Science (1987) 1.87
Protein docking and complementarity. J Mol Biol (1991) 1.86
Structure-based inhibitor design by using protein models for the development of antiparasitic agents. Proc Natl Acad Sci U S A (1993) 1.82
Blue light and bilirubin excretion. Science (1980) 1.81
Molecular docking to ensembles of protein structures. J Mol Biol (1997) 1.80
Regulation of clathrin assembly and trimerization defined using recombinant triskelion hubs. Cell (1995) 1.80
Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity. J Virol (1995) 1.78
The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem Biol (1997) 1.77
Configurational isomerization of bilirubin and the mechanism of jaundice phototherapy. Biochem Biophys Res Commun (1979) 1.76
Molecular cloning and primary structure of human 15-lipoxygenase. Biochem Biophys Res Commun (1988) 1.76
Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. Biochemistry (1998) 1.75
Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions. J Biol Chem (1993) 1.70
Mutational and secondary structural analysis of the basolateral sorting signal of the polymeric immunoglobulin receptor. J Cell Biol (1993) 1.68
Ligand solvation in molecular docking. Proteins (1999) 1.65
Turn prediction in proteins using a pattern-matching approach. Biochemistry (1986) 1.65
Definition and redesign of the extended substrate specificity of granzyme B. J Biol Chem (1998) 1.65
Intron-exon splice junctions map at protein surfaces. Nature (1982) 1.65
Characterization of globin domains: heme binding to the central exon product. Proc Natl Acad Sci U S A (1980) 1.63
Isolation and sequence of a rat chymotrypsin B gene. J Biol Chem (1984) 1.61
Structure-based discovery of inhibitors of thymidylate synthase. Science (1993) 1.61
The sequence, organization, and expression of the major cysteine protease (cruzain) from Trypanosoma cruzi. J Biol Chem (1992) 1.58
The role of singlet oxygen in bilirubin photo-oxidation. Biochem Biophys Res Commun (1971) 1.55
Human mast cell tryptase: multiple cDNAs and genes reveal a multigene serine protease family. Proc Natl Acad Sci U S A (1990) 1.55
Matching chemistry and shape in molecular docking. Protein Eng (1993) 1.53
Photobilirubin: an early bilirubin photoproduct detected by absorbance difference spectroscopy. Proc Natl Acad Sci U S A (1979) 1.53
A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation. Nat Cell Biol (2001) 1.51
Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry (1993) 1.51
The exocrine protein trypsinogen is targeted into the secretory granules of an endocrine cell line: studies by gene transfer. J Cell Biol (1985) 1.50
Introduction of a cysteine protease active site into trypsin. Biochemistry (1989) 1.50
The crystal structure of cruzain: a therapeutic target for Chagas' disease. J Mol Biol (1995) 1.49
Selective alteration of substrate specificity by replacement of aspartic acid-189 with lysine in the binding pocket of trypsin. Biochemistry (1987) 1.48
Molecular docking programs successfully predict the binding of a beta-lactamase inhibitory protein to TEM-1 beta-lactamase. Nat Struct Biol (1996) 1.48
Photodynamic therapy of malignant tumours. Lancet (1972) 1.48
A molecular dynamics simulation of polyalanine: an analysis of equilibrium motions and helix-coil transitions. Biopolymers (1991) 1.47
Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. Proc Natl Acad Sci U S A (1990) 1.46
A primary determinant for lipoxygenase positional specificity. Nature (1991) 1.45
Structure of the two related elastase genes expressed in the rat pancreas. J Biol Chem (1984) 1.43
Two approaches to discovering and developing new drugs for Chagas disease. Mem Inst Oswaldo Cruz (2009) 1.41
Immunologic and proteolytic analysis of HIV-1 reverse transcriptase structure. Virology (1990) 1.38
Studies of synthetic helical peptides using circular dichroism and nuclear magnetic resonance. J Mol Biol (1990) 1.38
Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D. Chem Biol (1997) 1.35
Nuclear magnetic resonance studies of xenon-129 with myoglobin and hemoglobin. Biochemistry (1982) 1.32
Real-time color graphics in studies of molecular interactions. Science (1981) 1.31
Preparation and properties of crystalline biliverdin IX alpha. Simple methods for preparing isomerically homogeneous biliverdin and [14C[biliverdin by using 2,3-dichloro-5,6-dicyanobenzoquinone. Biochem J (1980) 1.29
Mutants of bovine pancreatic trypsin inhibitor lacking cysteines 14 and 38 can fold properly. Science (1987) 1.29
Substrate specificity of trypsin investigated by using a genetic selection. Proc Natl Acad Sci U S A (1990) 1.29
Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. J Biol Chem (1990) 1.29
Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest (1995) 1.29
Structure-based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: irreversible inhibition of infectivity. J Virol (1997) 1.29
Turning green to gold. Nat Struct Biol (2001) 1.27
Flexible ligand docking using a genetic algorithm. J Comput Aided Mol Des (1995) 1.27
Calculation of protein tertiary structure. J Mol Biol (1976) 1.27
Production of crystallizable cruzain, the major cysteine protease from Trypanosoma cruzi. J Biol Chem (1993) 1.26
Tertiary structure in carboxypeptidase. J Am Chem Soc (1972) 1.25
Site-directed mutagenesis shows that tyrosine 248 of carboxypeptidase A does not play a crucial role in catalysis. Nature (1985) 1.25
Viral proteases: evolution of diverse structural motifs to optimize function. Cell (1997) 1.24
The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chem Biol (1999) 1.24
Structural determinants of specificity in the cysteine protease cruzain. Protein Sci (1997) 1.24
Amplification and sequencing of genomic DNA fragments encoding cysteine proteases from protozoan parasites. Mol Biochem Parasitol (1990) 1.23
Perturbing the polar environment of Asp102 in trypsin: consequences of replacing conserved Ser214. Biochemistry (1992) 1.22
Isolation and characterization of a cDNA encoding rat cationic trypsinogen. Biochemistry (1987) 1.22
Expression of cloned human reticulocyte 15-lipoxygenase and immunological evidence that 15-lipoxygenases of different cell types are related. J Biol Chem (1990) 1.21
The combinatorial distance geometry method for the calculation of molecular conformation. I. A new approach to an old problem. J Theor Biol (1983) 1.19
A new approach to the problem of docking two molecules: the ellipsoid algorithm. Biopolymers (1987) 1.18
Phototherapy for neonatal hyperbilirubinemia: efficacy, mechanism and toxicity. Adv Pediatr (1980) 1.17
Synthetic "interface" peptides alter dimeric assembly of the HIV 1 and 2 proteases. Protein Sci (1992) 1.17
A novel rat carboxypeptidase, CPA2: characterization, molecular cloning, and evolutionary implications on substrate specificity in the carboxypeptidase gene family. J Biol Chem (1988) 1.17
Distance measurements in spin-labeled lysozyme. Biochemistry (1984) 1.16
The sequence and reactive site of ecotin. A general inhibitor of pancreatic serine proteases from Escherichia coli. J Biol Chem (1991) 1.15